{"id":30770,"date":"2025-01-13T17:33:00","date_gmt":"2025-01-13T12:03:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30770"},"modified":"2025-01-13T17:16:51","modified_gmt":"2025-01-13T11:46:51","slug":"bms-dominance-in-molecular-glue-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape","title":{"rendered":"Bristol Mayer Squibb \u2014 The Undisputed Leader in the Molecular Glue Arena"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a3ff997d5503\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a3ff997d5503\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\/#Bristol_Myers_Squibb_%E2%80%94_Dominating_the_Molecular_Glue_Sector\" >Bristol Myers Squibb \u2014 Dominating the Molecular Glue Sector<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\/#Upcoming_Molecular_Glues_in_the_BMS_Pipeline\" >Upcoming Molecular Glues in the BMS Pipeline<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\/#Mezigdomide\" >Mezigdomide<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\/#Golcadomide\" >Golcadomide<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\/#Iberdomide\" >Iberdomide<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\/#Other_Companies_Developing_Molecular_Glues\" >Other Companies Developing Molecular Glues<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\/#What_Lies_Ahead\" >What Lies Ahead?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies. With its groundbreaking advancements, the company has redefined the potential of molecular glues in oncology, offering innovative solutions that precisely degrade harmful proteins. Bristol Myers Squibb\u2019s relentless commitment to scientific excellence and transformative research positions it at the forefront of this rapidly evolving field, paving the way for novel, life-changing treatments that address some of the most complex diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bristol-myers-squibb-dominating-the-molecular-glue-sector\"><span class=\"ez-toc-section\" id=\"Bristol_Myers_Squibb_%E2%80%94_Dominating_the_Molecular_Glue_Sector\"><\/span><strong>Bristol Myers Squibb \u2014 Dominating the Molecular Glue Sector<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Bristol Myers Squibb headquartered in New York City is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients with serious diseases. Currently, BMS is the only company with approved products and enjoying this monopoly in the molecular glue market. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/molecular-glues-competitive-landscape\">approved molecular glues<\/a> developed by BMS are <strong>REVLIMID, POMALYST, and Thalomid<\/strong>.&nbsp;<\/p>\n\n\n\n<p>REVLIMID is a prescribed medication for treating adults with multiple myeloma in combination with dexamethasone or as a maintenance treatment following autologous hematopoietic stem cell transplantation. It should not be used in individuals with chronic lymphocytic leukemia unless they are part of a controlled clinical trial. The safety and effectiveness of REVLIMID in children are not known.<\/p>\n\n\n\n<p>POMALYST is a prescribed medication used to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">adults with multiple myeloma<\/a>, in combination with dexamethasone, for patients who have already been treated with at least two other medications, including a proteasome inhibitor and lenalidomide, and whose condition worsens during or within 60 days of completing the last treatment. The safety and effectiveness of POMALYST in children have not been established.<\/p>\n\n\n\n<p>Thalomid (thalidomide) is a medication developed by Bristol Myers Squibb primarily used in the treatment of multiple myeloma, a type of blood cancer, and erythema nodosum leprosum, a complication of leprosy. Initially introduced in the late 1950s, it was withdrawn from the market due to its severe teratogenic effects, which caused birth defects.&nbsp;<\/p>\n\n\n\n<p>However, after rigorous studies, Thalomid was re-approved in the 1990s for its therapeutic benefits in specific conditions. It works by modulating the immune system and inhibiting the growth of blood vessels that supply tumors, playing a key role in the treatment of multiple myeloma. Thalomid\u2019s use is strictly controlled due to its risks, particularly during pregnancy, but it remains an important part of the treatment regimen for multiple myeloma, often used in combination with other chemotherapy agents.<\/p>\n\n\n\n<p><strong><em>Explore more about molecular glues at \u201c<a href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-molecular-glues\" class=\"ek-link\">The Rise of Molecular Glues: Transforming Protein-Protein Interactions into Therapeutic Opportunities<\/a>\u201d<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-upcoming-molecular-glues-in-the-bms-pipeline\"><span class=\"ez-toc-section\" id=\"Upcoming_Molecular_Glues_in_the_BMS_Pipeline\"><\/span><strong>Upcoming Molecular Glues in the BMS Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite being the only company with approved products in the molecular glue space, BMS is further strengthening its dominance by evaluating more molecular glue assets. Currently, the BMS\u2019 molecular glues pipeline consists of 3 candidates \u2014 Mezigdomide, Golcadomide, and Iberdomide. All these drugs are in the late stage of development.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mezigdomide\"><span class=\"ez-toc-section\" id=\"Mezigdomide\"><\/span><strong>Mezigdomide<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Cereblon E3 ligase modulators (CELMoD) are a type of oral immunomodulatory therapy developed to boost the immune system and directly target cancer cells by promoting the degradation of tumor-supporting proteins. Bristol Myers Squibb is exploring a new CELMoD drug, mezigdomide, for <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">multiple myeloma<\/a>. This agent was specifically designed to enhance the effectiveness of IMiD agents while maintaining manageable side effects, easy administration, and the potential to improve patient outcomes. Mezigdomide leverages cereblon to quickly trigger the degradation of target proteins Ikaros and Aiolos, thereby inhibiting tumor cell growth, encouraging tumor cell death, and activating immune-stimulatory effects.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"312\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171022\/Molecular-Glues-in-the-BMS-Pipeline-1024x312.png\" alt=\"Molecular-Glues-in-the-BMS-Pipeline\" class=\"wp-image-30773\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171022\/Molecular-Glues-in-the-BMS-Pipeline-1024x312.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171022\/Molecular-Glues-in-the-BMS-Pipeline-300x92.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171022\/Molecular-Glues-in-the-BMS-Pipeline-150x46.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171022\/Molecular-Glues-in-the-BMS-Pipeline-768x234.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171022\/Molecular-Glues-in-the-BMS-Pipeline-1536x468.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171022\/Molecular-Glues-in-the-BMS-Pipeline-2048x625.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-golcadomide\"><span class=\"ez-toc-section\" id=\"Golcadomide\"><\/span><strong>Golcadomide<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Golcadomide (CC-99282)<\/strong> is an oral molecular glue that facilitates the degradation of IKZF1\/3 transcription factors (Ikaros\/Aiolos) by interacting with the cereblon E3 ubiquitin ligase complex. It is a new thalidomide analog, classified as a CELMoD (cereblon E3 ligase modulator). Golcadomide exhibits immunomodulatory effects, with improved antiproliferative and proapoptotic properties. Currently, it is in Phase III development for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-lymphomas-market\">treatment of B-cell lymphoma<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-iberdomide\"><span class=\"ez-toc-section\" id=\"Iberdomide\"><\/span><strong>Iberdomide<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Iberdomide <\/strong>is an experimental oral immunomodulatory medication being developed for the treatment of multiple myeloma, a blood cancer marked by the growth of abnormal plasma cells in the bone marrow. A derivative of thalidomide, Iberdomide works by modulating the immune system and targeting the cereblon E3 ligase complex, which leads to the breakdown of specific proteins that support cancer cell survival and growth. This mechanism makes Iberdomide a promising treatment option in a field that includes other immunomodulatory drugs such as lenalidomide and pomalidomide. In December 2018, the US FDA designated iberdomide as an <strong>orphan drug<\/strong> for the treatment of multiple myeloma. The drug is undergoing Phase III clinical trials for treating multiple myeloma.<\/p>\n\n\n\n<p>Once approved, all these therapies will further give BMS an upper hand in the molecular glue landscape.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-other-companies-developing-molecular-glues\"><span class=\"ez-toc-section\" id=\"Other_Companies_Developing_Molecular_Glues\"><\/span><strong>Other Companies Developing Molecular Glues<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Apart from BMS, several other pharma companies are also trying their luck to enter the molecular glue arena and give stiff competition to the current market leader. Currently, <strong>50+ companies<\/strong> are working on their lead assets, although all these molecular glues are still in the early stages yet they have the potential to change the <a href=\"https:\/\/www.delveinsight.com\/report-store\/molecular-glues-competitive-landscape\">molecular glue competitive landscape<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"312\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171104\/Companies-Pioneering-Molecular-Glues-Research-1024x312.png\" alt=\"Companies-Pioneering-Molecular-Glues-Research\" class=\"wp-image-30774\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171104\/Companies-Pioneering-Molecular-Glues-Research-1024x312.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171104\/Companies-Pioneering-Molecular-Glues-Research-300x92.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171104\/Companies-Pioneering-Molecular-Glues-Research-150x46.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171104\/Companies-Pioneering-Molecular-Glues-Research-768x234.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171104\/Companies-Pioneering-Molecular-Glues-Research-1536x468.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171104\/Companies-Pioneering-Molecular-Glues-Research-2048x625.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The molecular glue companies evaluating their products include <strong>Eisai Co Ltd<\/strong> (E 7820), <strong>Monte Rosa Therapeutics, Inc.<\/strong> (MRT-2359), <strong>Revolution Medicines, Inc.<\/strong> (RMC 6291 and RMC-6236), <strong>InnoCare Pharma<\/strong> (ICP-490), <strong>C4 Therapeutics<\/strong> (CFT 7455), <strong>Nurix Therapeutics, Inc. <\/strong>(NX-5948 and NX-2127), <strong>Gluetacs Therapeutics<\/strong> (GT919), <strong>Plexium <\/strong>(PLX-4545), <strong>Novartis Pharmaceuticals<\/strong> (DKY709), <strong>Nested Therapeutics<\/strong> (NST-628), <strong>Salarius Pharmaceuticals, Inc.<\/strong> (SP-3164), and others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-lies-ahead\"><span class=\"ez-toc-section\" id=\"What_Lies_Ahead\"><\/span><strong>What Lies Ahead?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Molecular glues are set to revolutionize drug discovery, particularly in addressing previously \u201cundruggable\u201d targets, and Bristol Myers Squibb has positioned itself as a leader in this cutting-edge space. Molecular glues work by facilitating interactions between proteins, often targeting disease-causing proteins for degradation. BMS, with its strong track record in protein degradation therapies, exemplified by its development of cereblon-modulating compounds like lenalidomide and pomalidomide, is leveraging its expertise to expand into molecular glues. By investing in advanced technologies and forging collaborations, BMS is not only building a robust pipeline but also establishing proprietary platforms that could dominate this therapeutic class. These efforts are likely to give BMS a significant competitive edge in offering first-in-class or best-in-class therapies across oncology, immunology, and other areas.<\/p>\n\n\n\n<p>However, BMS is not the only player in the molecular glue race, and stiff competition from other pharmaceutical companies could challenge its lead. Rivals such as Novartis, Amgen, and smaller biotech firms like Arvinas and Kymera Therapeutics are also heavily investing in the development of molecular glues. These companies bring diverse approaches, including proprietary discovery platforms, partnerships with academic institutions, and breakthroughs in understanding protein-protein interactions. Additionally, new entrants and startups, often fueled by venture capital and innovative research, are accelerating the pace of innovation. This competitive landscape means that BMS must continuously innovate, secure intellectual property, and execute its pipeline effectively to maintain its leadership, as the potential of molecular glues attracts increasing attention and investment across the pharmaceutical industry.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/molecular-glues-competitive-landscape\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07141529\/Molecular-Glues-Competitive-Outlook-1024x194.png\" alt=\"Molecular Glues Competitive Outlook\" class=\"wp-image-30746\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07141529\/Molecular-Glues-Competitive-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07141529\/Molecular-Glues-Competitive-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07141529\/Molecular-Glues-Competitive-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07141529\/Molecular-Glues-Competitive-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07141529\/Molecular-Glues-Competitive-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/07141529\/Molecular-Glues-Competitive-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies. With its groundbreaking advancements, the company has redefined the potential of molecular glues in oncology, offering innovative solutions that precisely degrade harmful proteins. Bristol Myers Squibb\u2019s relentless commitment to scientific excellence and transformative research positions [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30776,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[784,22415,22410,22413,22412,22411,410],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-30770","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-bms","tag-bristol-mayer-squibb","tag-molecular-glues","tag-molecular-glues-competitive-landscape","tag-molecular-glues-landscape","tag-molecular-glues-market","tag-multiple-myeloma","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BMS \u2014 A Trailblazer in the Molecular Glue Landscape<\/title>\n<meta name=\"description\" content=\"Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS \u2014 A Trailblazer in the Molecular Glue Landscape\" \/>\n<meta property=\"og:description\" content=\"Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-13T12:03:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171148\/bms-dominance-in-molecular-glue-landscape.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BMS \u2014 A Trailblazer in the Molecular Glue Landscape","description":"Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape","og_locale":"en_US","og_type":"article","og_title":"BMS \u2014 A Trailblazer in the Molecular Glue Landscape","og_description":"Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies.","og_url":"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-01-13T12:03:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171148\/bms-dominance-in-molecular-glue-landscape.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape","url":"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape","name":"BMS \u2014 A Trailblazer in the Molecular Glue Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171148\/bms-dominance-in-molecular-glue-landscape.png","datePublished":"2025-01-13T12:03:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/bms-dominance-in-molecular-glue-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171148\/bms-dominance-in-molecular-glue-landscape.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171148\/bms-dominance-in-molecular-glue-landscape.png","width":466,"height":284,"caption":"bms-dominance-in-molecular-glue-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/13171148\/bms-dominance-in-molecular-glue-landscape-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BMS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bristol Mayer Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Molecular Glues<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">molecular glues competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Molecular Glues Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Molecular Glues Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BMS<\/span>","<span class=\"advgb-post-tax-term\">Bristol Mayer Squibb<\/span>","<span class=\"advgb-post-tax-term\">Molecular Glues<\/span>","<span class=\"advgb-post-tax-term\">molecular glues competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">Molecular Glues Landscape<\/span>","<span class=\"advgb-post-tax-term\">Molecular Glues Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jan 13, 2025","modified":"Updated on Jan 13, 2025"},"absolute_dates_time":{"created":"Posted on Jan 13, 2025 5:33 pm","modified":"Updated on Jan 13, 2025 5:16 pm"},"featured_img_caption":"bms-dominance-in-molecular-glue-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30770"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30770\/revisions"}],"predecessor-version":[{"id":30778,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30770\/revisions\/30778"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30776"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30770"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30770"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}